Haoma Medica Executives
The team of professionals at Haoma Medica has considerable expertise in the area of scientific and clinical development of pharmaceutical agents as well as global investment banking and management experience. Haoma Medica has decided to bring in strong senior managerial oversight in from day one to create detailed formal business plans for all products, develop multi year line item budgets, layout achievable project timelines and most importantly, drive the growth strategy. This will ensure that science and business are equally represented throughout all the growth phases of this company.
Dr Stephen Hodges, Founder & Executive Chairman, member of the Management & Scientific Board: is an Honorary Fellow at The Royal Veterinary College who discovered NaQuinate and has expertise derived from several academic environments working with established pharmaceutical companies, biotech companies and University-based drug and intellectual property development companies. Dr Hodges has a long history in medical research, which ideally places him to oversee the early phase developments of NaQuinate. Dr Hodges has stepped down from academic pursuits to co-manage the project.
Chief Executive Officer
|Ms. Carmen Greco, Founder & Chief Executive Officer, member of the Management and Scientific Board: has 22 years of global investment banking experience at the world’s leading financial institutions. She spent over fifteen years at Goldman Sachs as a Managing Director in New York and London and two years as a Managing Director at UBS in London. She has created and built up five separate businesses within the two organizations. Her teams focused on creating, developing and distributing both developed & emerging market risk management products to High Net Worth individuals, Institutions and Hedge fund clients around the world. Her considerable management skills, financial knowledge, branding & marketing experience, combined with her client contacts will be invaluable for the company. She will work most closely on a day to day basis with Dr. Stephen Hodges and Mr. Cenk Oguz.|
Chief Scientific Officer
Dr Robin Soper, Founder & Chief Scientific Officer, member of the Scientific Board: was a Senior Research Fellow with the Cancer Research UK Clinical Centre and has worked directly on the early development, from chemical synthesis through to testing the in vitro biological activity of NaQuinate. Dr Soper has also shown that NaQuinate has a limited adverse toxicity profile. Dr Soper will supervise laboratory developments and make presentations to learned societies at appropriate points.
Chief Medical Officer
Mr Cenk Oguz, Founder & Chief Medical Officer, member of the Management & Scientific Board: is a rising force in the orthopaedic surgery community and will be conducting the research in close co-operation with Dr Soper in order to secure the information that will lead to successful application to the MHRA for the human Phase I clinical trial. Mr Oguz will work in close contact with Professor Emery at St. Mary’s Hospital and the management Board London to ensure that the clinical trial is correctly completed and, importantly, he will make presentations to learned medical society meetings and conferences. Mr. Oguz is currently overseeing the Osteoporosis clinic at St Mary’s hospital, London. Dr Oguz will supervise laboratory developments and make presentations to learned societies at appropriate points.
Dr Andrew Pitsillides, Scientist, member of the Scientific Board: is a Reader in The Royal Veterinary College with an established academic career, marked as a ‘rising star’ of skeletal disease and skeletal development. Dr Pitsillides and Dr Hodges jointly oversaw the successful prosecution of NaQuinate as a potential osteoporosis drug and demonstrated it’s therapeutic potential. Dr Pitsillides will retain academic position and continue to add value to the ongoing studies.
Dr Dominic Harrington, Scientist, member of the Scientific Board: is a Senior Lecturer at King’s College London and he has developed techniques that are essential for the analytical prosecution of NaQuinate, and has recently demonstrated, in collaboration with Dr Hodges, that NaQuinate is absorbed following oral administration of the drug. A metabolic, pharmacodynamic and pharmacokinetic understanding of the consequences of administering NaQuinate are prerequisite components of the regulatory conditions for filing a licence application for human clinical trials in any major country. This component of the development will be done in close co-operation with Dr Hodges.
Professor Roger Emery, Clinical Consultant, member of the Scientific Board: is a leading orthopaedic surgeon at St Mary’s Hospital, Imperial College London. He has worked extensively in the field of fracture repair and other skeletal injury surgery. He has experience in, and knowledge of, the MHRA requirements to undertake a clinical study leading to Phase I and Phase II trials. Mr Emery will take a role as responsible consultant authority during the Phase I and Phase IIa trials.
Scientific Consultant to Haoma Medica
Dr Martin Shearer, Scientific Consultant to Haoma Medica: Dr Martin Shearer is a Consultant Clinical Scientist at St Thomas' Hospital. He is an internationally recognized expert in the field of vitamins, particularly in relation to the role of vitamin K in human health and disease and the development of analytical methods for the evaluation of vitamin K status. A particular interest is the role that vitamins play in bone health. Martin is the current or past recipient of research grants or contracts from prestigious academic or government institutions which include the Medical Research Council, UK Food Standards Agency; UK Department of Health, US FDA, and US National Institute of Health as well as charities such as the UK National Osteoporosis Society. He is author or co-author of over 150 peer-reviewed scientific articles, book chapters, or symposium proceedings and has edited a book on vitamin K. Since 1988 he has served on several National or International Expert Committees and Working Groups including those convened by the World Health Organisation, the Food & Agriculture Organization of the UN, UK Department of Health, and UK MHRA.
Scientific Consultant to Haoma Medica
Professor Tim Arnett, Scientific Consultant to Haoma Medica: Tim Arnett is Professor of Mineralised Tissue Biology at University College London (UCL). He is known internationally for his research in osteoclast and osteoblast biology, as well as for his widely reproduced bone images. Professor Arnett has authored many publications and received research grants from industry, the MRC, BBSRC, Arthritis Research UK, Wellcome Trust and the European Union. He currently serves on the editorial boards of several journals, is secretary of the European Calcified Tissue Society and president-elect of the Bone Research Society.
Clinical Consultant to Haoma Medica
Professor Alan Boyde, Clinical Consultant to Haoma Medica: Professor Alan Boyde began his career with a degree in dentistry, so it was somewhat natural to find himself interested in hard tissue biology and in particular bone. With 44 years research experience in the Dept of Anatomy, University College London (over half as Professor) his depth of experience in the understanding of the dynamics of bone biology is considerable. Currently as Professor of Biophysics, Oral Growth and Development, Barts and The London, Queen Mary he continues to bring a unique insight into bone biology.
Copyright © 2011 Haoma Medica Ltd. All rights reserved.